A major phase 3 clinical trial was widely expected to confirm the lipoprotein(a) [Lp(a)] hypothesis — that lowering it yields cardiovascular benefit. Harpreet Bhatia, MD When the disappointing results ...

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)--The Family Heart Foundation, a leading research, education and advocacy organization, today announced the publication of a new peer-reviewed study in JACC: ...

The much-anticipated Lp(a)HORIZON trial testing whether the novel drug pelacarsen can improve cardiovascular outcomes by decreasing lipoprotein(a) levels has failed to meet its primary endpoint.

Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

Please provide your email address to receive an email when new articles are posted on . Pelacarsen did not reduce cardiovascular events in patients with elevated lipoprotein(a) compared with placebo.

The result calls into question other late-stage trials testing Lp(a)-lowering drugs from the likes of Amgen and Eli Lilly. (iStock / Getty Images Plus) Novartis’ Ionis-partnered drug designed to lower ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Many people who face a heightened ...

When an agentic AI system hands a task from a small model to a larger one — or back down again — it pays a steep tax: the receiving model has to recompute the entire conversation from scratch, driving ...

Role Model is fully back. The musician has announced his third LP Chuck Timely & the Hourglass, the anticipated follow-up to his breakout album Kansas Anymore. The new album will arrive August 7, via ...

Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a ...